19-Dec-2025
Celldex (CLDX) Receives a Sell from Barclays
TipRanks (Wed, 17-Dec 4:18 AM ET)
Globe Newswire (Tue, 9-Dec 8:01 AM ET)
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 10-Nov 4:01 PM ET)
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Globe Newswire (Mon, 10-Nov 8:01 AM ET)
Celldex to Present at Upcoming Investor Conferences
Globe Newswire (Fri, 7-Nov 8:01 AM ET)
Globe Newswire (Thu, 30-Oct 4:01 PM ET)
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics trades on the NASDAQ stock market under the symbol CLDX.
As of December 19, 2025, CLDX stock price climbed to $25.60 with 1,482,806 million shares trading.
CLDX has a beta of 1.59, meaning it tends to be more sensitive to market movements. CLDX has a correlation of 0.27 to the broad based SPY ETF.
CLDX has a market cap of $1.70 billion. This is considered a Small Cap stock.
Last quarter Celldex Therapeutics reported $0 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.12.
In the last 3 years, CLDX traded as high as $53.18 and as low as $14.40.
The top ETF exchange traded funds that CLDX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
CLDX has underperformed the market in the last year with a price return of +0.9% while the SPY ETF gained +18.1%. However, in the short term, CLDX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.0% vs +2.8% return in SPY. But in the last 2 weeks, CLDX shares have been beat by the market, returning -13.1% compared to an SPY return of -0.5%.
CLDX support price is $24.52 and resistance is $26.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDX shares will trade within this expected range on the day.
